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Hemothorax in a Medical Intensive Care Unit:
Incidence, Comorbidity and Prognostic Factors
Chung-Yu Chen,1,2 Chia-Lin Hsu,1 Chia-Hsuin Chang,3 Kuan-Yu Chen,1* 
Chong-Jen Yu,1 Pan-Chyr Yang1
Background/Purpose: There is a lack of data regarding the occurrence of hemothorax in medical intensive
care units (ICUs). The purpose of this study was to investigate the incidence, comorbidity and prognostic
factors of hemothorax in medical ICU patients.
Methods: From January 1997 to December 2004, patients with hemothorax that developed during an ICU
stay were studied. Hemothorax was considered procedure-related if it developed within 24 hours after an
invasive procedure. Medical records were reviewed and analyzed with respect to patients’ demographic
data, underlying diseases, reasons for admission, Acute Physiology and Chronic Health Evaluation II score,
procedures related to hemothorax, management, duration of ICU stay, and outcomes.
Results: Fifty-three patients (0.79%) suffered hemothorax during their ICU stay. Chronic kidney disease
(77.4%) was the most common comorbidity. A total of 40 cases (75.5%) were procedure-related.
Thoracentesis and chest tube thoracostomy were the most common procedures. The 28-day mortality rate
was 35.8%. Multivariate logistic regression analysis revealed that a prothrombin time/international nor-
malized ratio ≥ 1.6 (odds ratio = 10.99, 95% confidence interval = 1.08–112.05) and a hemoglobin decrease
≥ 3 g/dL (odds ratio = 5.55, 95% confidence interval = 1.26–24.45) were significantly associated with 28-day
mortality.
Conclusion: Chronic kidney disease was the most common comorbidity associated with hemothorax.
Patients with chronic kidney disease might require close observation for hemothorax after invasive proce-
dures, such as thoracentesis and chest tube thoracostomy. Prolonged prothrombin time and decreased 
hemoglobin level might be of prognostic value for critically ill patients with hemothorax.
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In a previous study, hemothorax was found in
approximately 50% of patients with blunt chest
trauma.1 However, the incidence of hemothorax
in the intensive care unit (ICU) remains unclear.
Hemothorax has been reported in 1.0–3.4% of
critically ill patients with pleural effusion.2 In
another 1-year study in a medical ICU, four 
of 1351 patients had hemothorax.3 The occur-
rence of hemothorax might be underestimated,
given that, in a further previous study, only 82 of
113 patients with pleural effusion underwent
thoracentesis.4
The etiology of hemothorax in the ICU can be
either iatrogenic or spontaneous. The major causes
of hemothorax encountered in a medical ICU are
venous bleeding as a complication of thoracente-
sis, pleural biopsy, chest tube placement, or central
venous catheterization.4–6 In contrast, sponta-
neous hemothorax is uncommon. In some pa-
tients, no definite etiology of hemothorax can be
determined despite exploratory thoracostomy.7
Some studies have reported associated morbidity
such as malignant pleural disease, and anticoagu-
lation therapy in patients with spontaneous hemo-
thorax.8,9 There are a paucity of data regarding this
condition; hence, the causes of spontaneous he-
mothorax in the ICU warrant further investigation.
The occurrence of hemothorax in a medical
ICU setting has been seldom studied. In addition,
little is known about the mortality rate and prog-
nostic factors for hemothorax in critically ill pa-
tients. Therefore, in this study we investigated the
incidence, etiology, comorbidity, and outcomes
of hemothorax in a medical ICU.
Materials and Methods
Patients
From January 1997 to December 2004, patients
with a diagnosis of hemothorax who were admit-
ted to the 18-bed medical ICU of National Taiwan
University Hospital, Taipei, Taiwan (a 1500-bed
tertiary medical center) were eligible for inclusion.
The patients were identified from a computer reg-
istration database according to the coding system
of the International Classification of Diseases,
9th Revision. The diagnosis of hemothorax re-
quired that the following criteria were met: pleu-
ral effusion with a hematocrit > 50% of that of the
circulating hematocrit, or bloody pleural effu-
sion accompanied by a decrease in hemoglobin
≥ 1 g/dL within 24 hours, without other sources
of bleeding. Patients were excluded if hemotho-
rax was diagnosed before ICU admission, or if
the occurrence of hemothorax was established
after chest injury or thoracic/cardiovascular sur-
gery. The Institutional Review Board of National
Taiwan University Hospital approved this study.
The requirement for informed consent was waived
by the review board.
Hemothorax was considered procedure-related
if it occurred within 24 hours after the patient
had undergone any invasive procedure in the ICU;
otherwise, the etiology of hemothorax was consid-
ered spontaneous. Medical records were analyzed
for age, sex, underlying diseases, reason for ICU
admission, Acute Physiology and Chronic Health
Evaluation (APACHE) II score,10 platelet count,
the last value of prothrombin time [including the
international normalized ratio (INR) and activated
partial thromboplastin time] before hemothorax
occurred, occurrence of shock, volume of blood
components and coagulation factors received by
transfusion, invasive procedures performed be-
fore the occurrence of hemothorax (including tho-
racentesis, chest tube thoracostomy, central venous
catheterization, pulmonary artery catheterization,
pericardiocentesis, and transthoracic lung biopsy),
management (including number and duration of
chest tube placements), surgical intervention, dura-
tion of ICU and hospital stay, and patient outcome.
For the associated morbidity, heart disease 
included heart failure, arrhythmia, and coronary
artery disease. Lung disease included chronic 
obstructive pulmonary disease and pneumonia.
Chronic kidney disease was defined by signs of
kidney damage or kidney function impairment
for at least 3 months according to the National
Kidney Foundation guidelines (Kidney Dialysis
Outcomes Quality Initiative). Liver disease in-
cluded hepatitis and liver cirrhosis. Malignancies
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included solid tumors and hematological malig-
nancy. Autoimmune disease was defined as any
disorder caused by reactivity with immune system
components.
Coagulopathy was defined as abnormal pro-
thrombin time with prolonged INR. The INR
was calculated from the patient’s prothrombin
time and the international sensitivity index value.
Prolonged INR was defined as ≥ 1.2 times con-
trol. A diagnosis of thrombocytopenia was based
on a fall in the platelet count to < 150,000/μL. The
amount of blood components transfused immedi-
ately during the 72-hour period following the diag-
nosis of hemothorax was measured, and included
whole blood, packed red blood cells, pooled
platelets, fresh frozen plasma, and cryoprecipitate.
APACHE II scores were calculated using the
clinical data available during the first 24 hours 
of ICU stay. The reasons for ICU admission were
defined as the main problem that necessitated
admission. Hypovolemic shock was defined by
signs of poor perfusion, with a loss of at least 30%
of total blood volume, systolic blood pressure
< 90 mmHg, and the requirement for increasing
intravascular fluid supply or blood transfusion.
Surgical intervention for hemothorax was indi-
cated at our medical ICU if any one of the fol-
lowing conditions existed: > 1 L of blood was
evacuated immediately after tube thoracostomy;
bleeding from the chest continued at a rate of
150–200 mL/hr for 2–4 hours, or a persistent
blood transfusion was required to maintain hemo-
dynamic stability.
Statistical analysis
Continuous variables are expressed as the mean±
standard deviation, whereas categorical variables
are expressed as percentages. Quantitative vari-
ables were compared using independent samples
t test, whereas categorical variables were compared
using a χ2 test. A p value < 0.05 was considered
statistically significant. Multivariate logistic re-
gression analysis was performed for variables if 
p was <0.05. Statistical calculations were performed
using SPSS version 14.0 (SPSS Inc., Chicago, 
IL, USA).
Results
Patient characteristics
There were a total of 6746 admissions to our med-
ical ICU from January 1997 to December 2004.
A diagnosis of hemothorax was made in 77 of
these patients. Ten patients who had hemothorax
related to chest trauma and 14 who had hemoth-
orax as a complication of thoracic/cardiovascular
surgery were excluded. Thus 53 patients (0.79%)
were included. The demographic characteristics of
these patients are summarized in Table 1. Nineteen
patients were taking anticoagulation or under-
going antiplatelet therapy. Chronic kidney dis-
ease was the most common comorbidity (n = 41,
77.4%), and 16 of these patients required dialysis.
The reasons for admission to the ICU are listed
in Table 1. Most patients were admitted due to
sepsis/septic shock.
Etiology
There were 40 patients with procedure-related
hemothorax. Among these, 33 (82.5%) had chro-
nic kidney disease. Fourteen patients were receiving
Table 1. Clinical characteristics of 53 critically ill
patients with hemothorax*
Parameters
Age (yr) 67.8 ± 15.7
Sex, male 29 (54.7)
Underlying conditions
Chronic renal disease 41 (77.4)
Heart disease 18 (34.0)
Liver disease 16 (30.2)
Lung disease 13 (24.5)
Diabetes 13 (24.5)
Malignancy 10 (18.9)
Autoimmune disease 3 (5.7)
Reasons for admission to ICU
Sepsis/septic shock 24
Pneumonia/respiratory failure 21
Heart failure 7
Consciousness disturbance 1
Procedure-related 40 (75.5)
*Data presented as mean ± standard deviation or n (%). ICU =
Intensive care unit.
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antiplatelet therapy while these procedures were
being performed. Thoracentesis (n = 20) and chest
tube thoracostomy (n = 13) were the most com-
mon associated procedures. There were 3233
thoracenteses and 592 chest tube thoracostomies
performed in our medical ICU between 1997 and
2004. The overall complication rates of hemo-
thorax because of thoracentesis and chest tube
thoracostomy were 0.6% and 2.2%, respectively
(Table 2).
There were 13 patients with a diagnosis of spon-
taneous hemothorax (Table 3). Three of these had
Table 3. Characteristics of 13 patients with spontaneous hemothorax
Case
Age
Comorbidity
Hb decrease Platelet PT Cr 
Management
28-day
(yr)/sex (g/dL) (/μL) (INR) (mg/dL) outcome
1 66/M CRD 4.3 74 1.42 2.90 VATS Death
2 93/M Sick sinus syndrome 1.3 196 1.11 1.00 SC Death
3 76/F ESRD 0.5 148 1.53 3.80 CTT Death
4 71/F Lung cancer 3.9 66 1.28 0.88 CTT Death
5 61/M CRD; liver cirrhosis 4.1 171 1.66 0.89 CTT Death
6 27/M Leukemia 2.3 34 1.20 2.60 VATS Survival
7 60/M CRD; liver cirrhosis 1.0 38 1.57 3.10 CTT Survival
8 49/M CRD; liver cirrhosis 2.3 48 1.26 3.00 SC Survival
9 87/F CRD 1.1 377 1.16 1.46 SC Survival
10 51/M ESRD; liver cirrhosis 3.0 63 1.53 7.30 CTT Survival
11 45/M Pulmonary tuberculosis 0.3 17 1.50 0.80 VATS Survival
12 42/M Liver cirrhosis 0.5 115 3.13 2.60 CTT Survival
13 72/F Coronary artery disease 1.2 359 1.25 0.80 CTT Survival
M = Male; F = female; Hb = hemoglobin; PT = prothrombin time; INR = international normalized ratio; Cr = creatinine; CRD = chronic renal
disease; ESRD=end-stage renal disease; VATS=video-assisted thoracoscopic surgery. CTT=chest tube thoracostomy; SC= supportive care.
Table 2. Procedures related to hemothorax in 
a medical intensive care unit
Procedure Total
Overall 
complication (%)
Thoracentesis 3233 20 (0.6)
Chest tube thoracotomy 592 13 (2.2)
Central venous 4534 4 (0.1) 
catheterization*
Pericardiocentesis 35 2 (5.7)
Percutaneous transhepatic 91 1 (1.1) 
cholangiogram with
drainage
*Including internal jugular venous catheterization, subclavian 
venous catheterization, and pulmonary artery catheterization.
coagulopathy, and eight had both coagulopathy
and thrombocytopenia. Seven patients had chronic
kidney disease, and five had liver cirrhosis. Five
patients (cases 2, 4, 5, 9 and 13) were receiving
antiplatelet therapy when hemothorax developed.
Two patients had malignancies: one with lung can-
cer (case 4) and one with acute leukemia (case 6).
Treatment and outcome
Clinical courses and outcomes are summarized in
Table 4. A total of 19 patients (35.8%) died within
28 days. Among these, 10 expired due to hypo-
volemic shock related to hemothorax, and the re-
maining nine died due to septic shock. For patients
with procedure-related hemothorax (n = 40), 28
received tube thoracostomy and two underwent
video-assisted thoracic surgery. The 28-day mor-
tality rate for patients with procedure-related he-
mothorax was 35.0% (n = 14). For patients with
spontaneous hemothorax (n = 13), eight received
tube thoracostomy and three patients underwent
video-assisted thoracic surgery. The 28-day mor-
tality rate for patients with spontaneous hemo-
thorax was 38.5% (n = 5).
Patient characteristics and management were
analyzed for possible prognostic factors of iatro-
genic and spontaneous hemothorax. There was no
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significant difference in either mortality rate or
prognostic factors between these two subgroups.
Prognostic factors
We investigated the differences in clinical features
between the survival and non-survival groups.
The survival group had lower INR levels (survival
vs. non-survival = 1.33 ± 0.41 vs. 2.16 ± 1.76, p =
0.018) and a less pronounced hemoglobin de-
crease (survival vs. non-survival = 2.36 ± 1.77 g/dL
vs. 3.53±1.53g/dL, p=0.019). There were no statis-
tically significant differences between the survival
and non-survival groups for the other variables,
including age, sex, APACHE II score, reason for
admission, comorbidity, etiology (spontaneous vs.
iatrogenic), partial thromboplastin time, platelet
count, albumin level, blood urea nitrogen, crea-
tinine, and type of management.
Multivariate analysis revealed that pro-
thrombin time INR ≥ 1.6 [p = 0.043, odds ratio
(OR) = 10.99, 95% confidence interval (CI) =
1.08–112.05] and hemoglobin decrease ≥ 3 g/dL
(p = 0.024, OR = 5.55, 95% CI = 1.26–24.45) were
significantly associated with 28-day mortality
(Table 5). With each 1-g/dL decrease in hemo-
globin, the relative risk of 28-day mortality in-
creased by 55.4%. If the INR level increased by
0.1 from 1.0, the relative risk of 28-day mortality
increased by 32.2%.
Discussion
In this study, we demonstrated that the incidence
of hemothorax in a medical ICU was 0.79%.
Chronic kidney disease was the most common
associated morbidity. Most cases of hemothorax
were procedure-related, with thoracentesis and
chest tube thoracostomy being the most com-
mon related procedures. The prothrombin time
Table 4. Clinical features and outcomes of 53 critically ill patients with hemothorax
Clinical features and courses Survival (n = 20) Non-survival (n = 33) p
APACHE II score 28.4 ± 5.3 27.4 ± 4.8 0.517
White cell count (/μL) 12,145.3 ± 7407.9 15,005.8 ± 10,901.5 0.315
Hemoglobulin (g/dL) 8.4 ± 1.7 8.0 ± 2.4 0.457
Platelet count (/μL) 135.3 ± 93.9 120.2 ± 114.7 0.605
Prothrombin time (sec) 15.7 ± 6.3 22.7 ± 17.4 0.141
Creatinine (mg/dL) 2.5 ± 2.5 1.9 ± 1.4 0.258
Aspartate aminotransferase (U/L) 52.7 ± 19.6 51.4 ± 33.8 0.906
Decrease of hemoglobin (g/dL) 2.36 ± 1.77 3.53 ± 1.53 0.019
Decrease of platelet count (/μL) 37.9 ± 36.8 55.3 ± 53.9 0.279
International normalized ratio 1.33 ± 0.41 2.16 ± 1.76 0.018
Management
CTT with drainage 11 (55.0) 24 (72.7)
Thoracentesis with drainage 4 (20.0) 4 (12.1)
VATS 2 (10.0) 3 (9.1)
Conservative treatment and/or 3 (15.0) 2 (6.1)
blood component therapy
Outcome
ICU stay (d) 37.1 ± 37.1 26.9 ± 26.9 0.253
Hospital stay (d) 80.4 ± 56.8 43.8 ± 40.6 0.008
APACHE II = Acute Physiology and Chronic Health Evaluation II; CTT = chest tube thoracostomy; VATS = video-assisted thoracoscopic
surgery; ICU = intensive care unit.
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INR and the level of hemoglobin decrease were
identified as potential prognostic factors.
Thoracentesis has traditionally been per-
formed widely in the ICU for patients with pleu-
ral effusion. Doyle et al reported that only two
patients developed hemothorax after 174 thora-
centesis procedures in 110 patients.11 Bass et al
identified only two cases of hemothorax out of a
total of 100 thoracentesis procedures performed
in 100 patients with hematologic malignancies.12
In a 1-year study in which 1640 patients were ad-
mitted to the medical ICU, 118 thoracenteses were
performed in 94 febrile patients, with hemotho-
rax occurring in two of these.13 In the same study,
the complication rate of hemothorax that resulted
from thoracentesis was 0.6%.
In our ICU, transthoracic sonography was per-
formed routinely before thoracentesis to estimate
pleural effusion volume. Guidance by transtho-
racic sonography might be useful to decrease the
incidence of hemothorax associated with thora-
centesis. Prior studies reported incidences of he-
mothorax complicating tube thoracostomy of
3–36% in the ICU.14,15 Etoch et al analyzed fac-
tors related to complications during this proce-
dure in a single trauma center.16 They have reported
that 379 patients required 599 tube thoracoto-
mies, with hemothorax occurring as a complica-
tion in 16 of these patients.16
Tube thoracostomy is associated with signifi-
cant morbidity. It has been reported that differences
in complication rates vary between physicians,
which suggests that additional training is indicated
in some instances.17 In our medical ICU, tube
thoracostomy was performed by senior physi-
cians with the aid of transthoracic sonography.
There were 13 cases of hemothorax (2.2%) which
resulted from complications of 592 chest tube
thoracostomies. Tube thoracostomy performed
after sonographic evaluation to determine the lo-
cation and amount of pleural effusion might be
helpful to decrease the occurrence of hemothorax.
Chronic kidney disease was the most common
comorbidity in our study. Uremic patients are
known to suffer bleeding diathesis due to
platelet dysfunction, with occurrence of pleural
hemorrhage after invasive procedures, which has
been highlighted in several case reports.18,19
Vanherweghem et al reviewed the complications
related to subclavian catheterization for he-
modialysis.20 In that review, major complications
such as pneumothorax and hemothorax that were
related to the subclavian route for dialysis occurred
in 22 patients who had 1288 catheter insertions.
This reflects a 1.7% rate of traumatic complication
in patients who are receiving dialysis.20 McVay 
et al demonstrated that patients with markedly
elevated serum creatinine levels (6.0–14.0 mg/dL)
had a significantly greater average decrease in 
hemoglobin [–0.82 ± 1.3 g/dL (n = 11) vs. –0.12 ±
0.88 g/dL (n = 450), p = 0.011], compared with
patients who had normal serum creatinine levels
(0.4–1.4 mg/dL), after paracentesis and thoracen-
tesis in a group with mild coagulation abnormal-
ities.21 Uremia-related bleeding diathesis might
contribute to iatrogenic hemothorax in the medical
Table 5. Variables that significantly influenced the 28-day mortality of 53 critically ill patients with
hemothorax
Variable
Number of patients Multivariate analysis
Total Number of death (%) OR (95% CI)
Prothrombin time INR
< 1.6 45 12 (26.7) 1
≥ 1.6 8 7 (87.5) 10.99 (1.08–112.05)
Hemoglobin decrease (g/dL)
< 3 31 6 (19.4) 1
≥ 3 22 13 (59.1) 5.55 (1.26–24.45)
INR = International normalized ratio; OR = odds ratio; CI = confidence interval.
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ICU. Therefore, patients with CKD might require
close observation for hemothorax after invasive
procedures, such as thoracentesis and chest tube
thoracostomy.
The occurrence of spontaneous hemothorax is
rare. We reported 13 patients with spontaneous
hemothorax. Eleven of these were diagnosed with
coagulopathy or thrombocytopenia. Five patients
(2 with atrial fibrillation, 2 with coronary artery
disease and 1 with ischemic stroke) received an-
tiplatelet therapy. Only two patients had active
malignancies, however, in these patients, hemotho-
rax was not related to pleural metastasis. Martinez
et al described six cases of spontaneous hemotho-
rax and also have reviewed the literature from
1862 to 1991 for additional cases.17 A total of 18
hemothorax cases have been reported in native
coagulopathy, including hemophilia, thrombocy-
topenia, and von Willebrand disease. Hemothorax
occurred in 1.5% of hemophilia cases.22 Fourteen
cases of hemothorax that resulted from complica-
tions related to anticoagulation therapy have been
reported.17 There have been four reported cases
of malignancies causing hemothorax without in-
vading the pleura (2 rib Ewing sarcomas, 1 lung
cancer, and 1 chronic myelocytic leukemia).17
In our study, increased prothrombin time
INR was significantly associated with 28-day mor-
tality. Prothrombin time has been identified as an
independent prognostic factor in previous studies
pertaining to major trauma. Murray et al studied
840 patients with traumatic brain injury, from
three of the relevant studies within the Interna-
tional Mission for Prognosis and Clinical Trial
(IMPACT) database.23 Prolonged prothrombin
time was associated with poor prognosis (OR =
1.64, 95% CI = 1.34–2.00). Kawai et al analyzed
abnormalities in preoperative laboratory data in
101 patients who underwent surgery for colorectal
perforations.24 Prolonged prothrombin time (sur-
vivors vs. non-survivors = 84.6 ± 14.9% vs. 62.2 ±
17.2) and activated partial thromboplastin time
[survivors vs. non-survivors = 31.5 ± 7.3 sec vs.
47.1 ± 15.8 sec) were significantly correlated with
poor prognosis. Among the several risk factors an-
alyzed, the presence of coagulation disorders
(prothrombin time < 70% of control or activated
partial thromboplastin time > 40 sec) was an in-
dependent predictive factor of postoperative mor-
tality. Further investigation to derive the prognostic
value of prothrombin time and explore the clini-
cal impact of aggressively correcting coagulation
abnormalities might be warranted.
There were several limitations to our study.
First, the case number was small and much varia-
tion could not be investigated. Second, hemo-
thorax was diagnosed by the analysis of pleural
effusion. When pleural effusion was first detected
upon physical examination or chest radiography,
thoracentesis was performed in accordance with
published guidelines.25–27 Therefore the incidence
of hemothorax could have been underestimated.
Third, because of the retrospective study design, no
standard protocol could be followed with regards
to the detection and management of hemothorax.
In conclusion, chronic kidney disease was most
commonly associated with hemothorax. Patients
with chronic kidney disease might require close
observation for hemothorax after invasive pro-
cedures, such as thoracentesis and chest tube
thoracostomy. Assessment of prothrombin time
INR and hemoglobin levels could be of prognostic
value in critically ill patients with hemothorax.
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